Novel Recombinant BCG Coexpressing Ag85B, ESAT-6 and Rv2608 Elicits Significantly Enhanced Cellular Immune and Antibody Responses in C57BL/6 Mice

Scandinavian Journal of Immunology

Volumn 76, Issue 3, 2012, Pages 271-277

  Lu, Y ^a   Xu, Y ^a   Yang, E ^a   Wang, C ^a   Wang, H ^a   Shen, H ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; RECOMBINANT BCG::AG85B ESAT6 RV2608 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; TUBERCULOSIS;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; BLOTTING, WESTERN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; TUBERCULOSIS; VACCINES, SYNTHETIC;

EID: 84865393423     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02726.x     Document Type: Article

References (34)

1. The Henry J Kaiser Family Foundation. The global tuberculosis epidemic. U.S. Global Health Policy. Washington, DC: The Henry J Kaiser Family Foundation, 2010.
2. Pablos-Méndez A, Raviglione MC, Laszlo A et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;338:1641-9.
3. Norazmi MN, Mustaffa M. Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine. Tuberculosis 2004;84:102-9.
4. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: ASM Press, 1994:531-57. ISBN 1-55581-072-1.
5. Fine PE, Rodrigues LC. Modern vaccines: mycobacterial diseases. Lancet 1990;335:1016-20.
6. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45.
7. Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 1992;56:648-61.
8. Horwitz MA, Harth G, Dillon BJ, Masleša-Galić S. Recombinant Bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97:13853-8.
9. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003;71:1672-9.
10. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000;68:791-5.
11. Andersen P, Andersen AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 1995;154:3359-72.
12. Cole ST. Comparative and functional genomics of the Mycobacterium tuberculosis complex. Microbiology 2002;148:2919-28.
13. Chaitra MG, Nayak R, Shaila MS. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant. Vaccine 2007;25:7168-76.
14. Vipond J, Vipond R, Allen-Vercoe E et al. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge. Vaccine 2006;24:6340-50.
15. Chakhaiyar P, Nagalakshmi Y, Aruna B et al. Regions of high antigenicity within the hypothetical PPE major polymorphic tandem repeat open-reading frame, Rv2608, show a differential humoral response and a low T cell response in various categories of patients with tuberculosis. J Infect 2004;190:1237-44.
16. Bertholet S, Ireton GC, Kahn M et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 2008;181:7948-57.
17. 190-198-mtb8.4 in C57/BL6 mice. Scand J Immunol 2008;67:133-9.
18. Shen H, Wang C, Yang E et al. Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-α induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice. Microbiol Immunol 2010;54:435-41.
19. Bao L, Chen W, Zhang H, Wang X. Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis Bacille Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun 2003;71:1656-61.
20. Martin RM, Lew AM. Is IgG2a a good Th1 marker in mice? Immunol Today 1998;19:49.
21. Derrick SC, Yang AL, Morris SL. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004;23:780-8.
22. Chensue SW, Warmington KS, Ruth JH, Lincoln P, Kunkel SL. Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Local and regional participation of IFN-gamma, IL-10, and TNF. J Immunol 1995;154:5969-76.
23. Young SL, O'Donnell MA, Buchan GS. IL-2-secreting recombinant Bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosuppression to elicit a Type 1 immune response. Int Immunol 2002;14:793-800.
24. Caruso AM, Serbina N, Klein E et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999;162:5407-16.
25. Smith SM, Malin AS, Pauline T et al. Characterization of human Mycobacterium bovis Bacillus Calmette-Guerin-reactive CD8+ T cells. Infect Immun 1999;67:5223-30.
26. Serbina NV, Flynn JL. Early emergence of CD8+ T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice. Infect Immun 1999;67:3980-8.
27. Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989;11 (Suppl. 2):S353-9.
28. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992;89:12013-7.
29. + T cell lines. Eur J Immunol 1988;18:59-66.
30. + T-lymphocytes in intracellular microbial infections. Immunol Today 1988;9:168-74.
31. Ordway DJ, Martins MS, Costa LM et al. Increased IL-4 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease. Acta Med Port 2005;18:27-36.
32. Neeraj D, Vivek R, Anil KT. Skewing of the Th1/Th2 responses in mice due to variation in level of expression of an antigen in a recombinant BCG system. Immunol Lett 2003;88:175-84.
33. Hovav AH, Mullerad J, Davidovitch L et al. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect Immun 2003;71:3146-54.
34. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.